A Phase 2 interventional study of MK0457 in Leukemia, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-26.
Sponsored by Merck Sharp & Dohme LLC · Phase 2, Interventional, and Treatment
This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 52 is above the median of 38 across 4,247 interventional studies indexed under Leukemia.
Browse Leukemia studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 133 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
continuous infusion every 14 days
Drug: MK0457
IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
efficacy
Time frame: 24 Months
No study locations are listed for this record.
This study is terminated, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck Sharp & Dohme LLC